Phaseline

Targets › MAGE2

MAGE2 (Melanoma-associated antigen 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Sep 2027.

Reduces p53/TP53 transactivation function through recruitment of HDAC3 to p53/TP53 transcription sites. Also represses p73/TP73 activity. (UniProt, P43356)

Open in Phaseline: the race on MAGE2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Fondazione Ricerca TraslazionaleTedopi
Cancer vaccine inducing cytotoxic T-lymphocytes against tumor-associated antigens (CEA, p5
CEA, TP53, ERBB2, MAGE2, MAGE3Phase 2Metastatic Non Small Cell Lung CancerSep 2027

Conditions

Metastatic Non Small Cell Lung Cancer (1)

Modalities

mixed (1)

Companies

Fondazione Ricerca Traslazionale (1)

Related targets

CEA (1) TP53 (1) ERBB2 (1) MAGE3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.